

DRUG PRIOR AUTHORIZATION COMMITTEE

September 16, 20109

TENTATIVE AGENDA

10:00 - 10:05	Welcome, Announcements and Introductions	Henry Petry, Chairman
10:05 - 10:15	Minutes Review	Discussion/ Approval
10:15- 11:15	Pharmacy Program/ Budget Update	George Oestreich/ Andrew Haslag
11:15 - 11:20	DUR Update	Tisha McGowan

Old Business

11:20 – 11:30	a. Implementation Schedule (Criteria for Previously Approved Clinical Edits, Step Therapies and PA's)	Rhonda Driver
---------------	---	---------------

New Business

11:30 – 11:45	a. Proposed Actions- New Drug/Product Reviews (See website and Attached Summary)	Rhonda Driver
	i. Open Access	
	ii. Clinical Edit/Step Therapy	
	iii. PDL Products	
	iv. Prior Authorization	
	• Discussion	
	• Public Hearing	
	• Decision	
	b. Clinical Edits	
	i. Smoking Cessation in Pregnant Women	
	• Discussion	
	• Public Hearing	
	• Decision	

1:45:1:00

	c. <u>Preferred Drug List (PDL)</u>	
	i. Ace Inhibitors	
	• Discussion	
	• Public Hearing	
	• Decision	
	ii. Ace Inhibitor/Diuretic Combination	
	• Discussion	
	• Public Hearing	
	• Decision	
	iii. Ace Inhibitor/Calcium Channel Blocker Combination	
	• Discussion	
	• Public Hearing	
	• Decision	
	iv. Alpha-Glucosidase Inhibitors	
	• Discussion	
	• Public Hearing	
	• Decision	
	v. Alzheimer's Agents	
	• Discussion	
	• Public Hearing	
	• Decision	
	vi. Angiotensin Receptor Blocker	
	• Discussion	
	• Public Hearing	
	• Decision	

- vii. **Angiotensin Receptor Blocker/Diuretic Combination**
 - Discussion
 - Public Hearing
 - Decision
- viii. **Antidiabetic Combination Agents**
 - Discussion
 - Public Hearing
 - Decision
- ix. **Biguanides**
 - Discussion
 - Public Hearing
 - Decision
- x. **Bone Ossification Suppression Agents/Calcitonins**
 - Discussion
 - Public Hearing
 - Decision
- xi. **Direct Renin Inhibitor**
 - Discussion
 - Public Hearing
 - Decision
- xii. **Direct Renin Inhibitor Combinations**
 - Discussion
 - Public Hearing
 - Decision
- xiii. **Electrolyte Depletors**
 - Discussion
 - Public Hearing
 - Decision
- xiv. **Herpes Antivirals**
 - Discussion
 - Public Hearing
 - Decision
- xv. **Immunomodulators/RA Agents (DMARDs)**
 - Discussion
 - Public Hearing
 - Decision
- xvi. **Leukotriene Modifiers**
 - Discussion
 - Public Hearing
 - Decision
- xvii. **Lipotropics-Niacin Preparations**
 - Discussion
 - Public Hearing
 - Decision
- xviii. **Low Sedating Antihistamines**
 - Discussion
 - Public Hearing
 - Decision
- xix. **Low Sedating Antihistamine/Decongestant Combinations**
 - Discussion
 - Public Hearing
 - Decision
- xx. **Macrolides Adult/Pediatric**
 - Discussion
 - Public Hearing
 - Decision
- xxi. **Meglitinides**
 - Discussion
 - Public Hearing
 - Decision

- xxii. **Multiple Sclerosis Agents**
 - Discussion
 - Public Hearing
 - Decision
- xxiii. **Narcotics: Long Acting**
 - Discussion
 - Public Hearing
 - Decision
- xxiv. **Nasal Steroids**
 - Discussion
 - Public Hearing
 - Decision
- xxv. **Ophthalmic Antihistamines**
 - Discussion
 - Public Hearing
 - Decision
- xxvi. **Ophthalmic Mast Cell Stabilizers**
 - Discussion
 - Public Hearing
 - Decision
- xxvii. **Ophthalmic Quinolones**
 - Discussion
 - Public Hearing
 - Decision
- xxviii. **Ophthalmic Prostaglandin Agonists**
 - Discussion
 - Public Hearing
 - Decision
- xxix. **Pulmonary Hypertension Agents(Oral/Inhaled/Injectable)**
 - Discussion
 - Public Hearing
 - Decision
- xxx. **Otic Quinolones**
 - Discussion
 - Public Hearing
 - Decision
- xxxi. **Quinolones-Systemic**
 - Discussion
 - Public Hearing
 - Decision
- xxxii. **2nd Generation Sulfonylureas**
 - Discussion
 - Public Hearing
 - Decision
- xxxiii. **Serotonin Receptor Agonists (Triptans)**
 - Discussion
 - Public Hearing
 - Decision
- xxxiv. **Thiazolidinediones**
 - Discussion
 - Public Hearing
 - Decision
- xxxv. **Topical Agents for Psoriasis**
 - Discussion
 - Public Hearing
 - Decision
- xxxvi. **Topical Retinoids**
 - Discussion
 - Public Hearing
 - Decision

- xxxvii. **Ulcerative Colitis Agents/Oral and Rectal**
 - Discussion
 - Public Hearing
 - Decision
 - xxxviii. **Vaginal Antibiotics**
 - Discussion
 - Public Hearing
 - Decision
 - xxxix. **Intranasal Antihistamines**
 - Discussion
 - Public Hearing
 - Decision
 - xl. **Cryptin Associated Periodic Syndrome Agents**
 - Discussion
 - Public Hearing
 - Decision
 - xli. **Self –Injectable Epinephrine Agents**
 - Discussion
 - Public Hearing
 - Decision
 - xlii. **Tramadol Like Agents**
 - Discussion
 - Public Hearing
 - Decision
 - xliii. **Fibromyalgia Agents**
 - Discussion
 - Public Hearing
 - Decision
- d. **Preferred Drug List**
- i. Process Discussion
 - ii. Therapeutic classes/To be announced at meeting.

1:00

LUNCH

1:15-1:30

Program Utilization Information

Rhonda Driver

1:30-1:50

Other Business

- *“Top 25” Drugs by Cost*
- *Clinical Edit Summary Report*
- *Call Center Statistics*

*Informal comments will be accepted from members of the audience at various points in the agenda.
Times noted are approximate, Agenda may move more quickly*

Executive Session

1:50-1:55

Minutes Review

Discussion/Approval

1:55-2:30

Case Reviews

Jenna Twehus

NEXT MEETING: DECEMBER 16, 2010